LY2835219 choline chloride Ruebsamen-Schaeff H

Ruebsamen-Schaeff H

Omarigliptin is currently in phase 3 clinical development

4'-tetramine hydrochloride

LIBSA--a method for the determination of ligand-binding preference to allosteric sites on receptor ensembles

InChiKey: PWYAUIUPDMSWJH-UGSOOPFHSA-N

LY2835219 choline chloride Ruebsamen-Schaeff HAbemaciclib, also known as LY2835219, is orally available cyclin dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. LY2835219 inhibits CDK4 and CDK6 with low nanomolar potency. LY2835219 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK mediated G1 S